Clare Ozawa

Clare R.
Ozawa is currently Director at Inception Sciences, Inc. since 2017, Director at Inception IBD, Inc., 858 Therapeutics, Inc., Jengu Therapeutics, Inc., Capsida Biotherapeutics, Inc., Stablix, Inc., and Kate Therapeutics, Inc., and Managing Director at Versant Venture Management LLC since 2017.
Former roles include Chief Executive Officer at McKinsey & Co., Inc. in 2006, Chief Executive Officer at Novartis Pharma AG from 2006 to 2008, Independent Director at Oyster Point Pharma, Inc. from 2019 to 2023, Director at Contineum Therapeutics, Inc., and Investment Professional at Versant Venture Management LLC from 2008 to 2010.
Education includes undergraduate studies at Stanford University and a doctorate from Stanford University School of Medicine conferred in 2002.